FAQ: Tonix Pharmaceuticals Added to Russell 3000 and Russell 2000 Indexes

What is the significance of Tonix Pharmaceuticals being added to the Russell 3000 and Russell 2000 Indexes?

The inclusion signifies Tonix Pharmaceuticals’ market cap growth and enhances its visibility among investors, as the Russell indexes are widely used benchmarks with $10.6 trillion in assets tied to their performance.

When will Tonix Pharmaceuticals’ inclusion in the Russell indexes take effect?

The inclusion is effective as of June 30, following the 2025 Russell indexes reconstitution.

What product is Tonix Pharmaceuticals preparing for potential FDA approval?

Tonix Pharmaceuticals is preparing for the potential FDA approval and launch of TNX-102 SL, a product candidate for the management of fibromyalgia, which has completed two statistically significant phase 3 studies.

What other developments are mentioned regarding Tonix Pharmaceuticals?

Tonix is also developing TNX-102 SL for acute stress reaction, has a contract with the U.S. DoD for up to $34 million to develop TNX-4200, and has a development portfolio focused on CNS disorders, immunology, rare diseases, and infectious diseases.

Where can I find more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their website at www.TonixPharma.com and in the company’s newsroom at https://ibn.fm/TNXP.

What is the Fast Track designation granted to TNX-102 SL by the FDA?

The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia, indicating the agency’s recognition of the drug’s potential to address an unmet medical need.

What are the implications of Tonix Pharmaceuticals’ inclusion in the Russell indexes?

The inclusion is expected to boost Tonix’s visibility and attractiveness to investors, potentially facilitating its progress toward commercialization of TNX-102 SL and other product candidates.